C
Cathy Hardalo
Researcher at Merck & Co.
Publications - 4
Citations - 1531
Cathy Hardalo is an academic researcher from Merck & Co.. The author has contributed to research in topics: Tedizolid & Internal medicine. The author has an hindex of 2, co-authored 3 publications receiving 1393 citations.
Papers
More filters
Journal ArticleDOI
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Oliver A. Cornely,Johan Maertens,Drew J. Winston,John R. Perfect,Andrew J. Ullmann,Thomas J. Walsh,David Helfgott,Jerzy Holowiecki,Dick Stockelberg,Yeow Tee Goh,Mario Petrini,Cathy Hardalo,Ramachandran Suresh,David Angulo-Gonzalez +13 more
TL;DR: In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazoles prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival.
Journal ArticleDOI
Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.
Cathy Hardalo,Thomas P. Lodise,Monique R. Bidell,Shawn Flanagan,Carisa De Anda,Steven Anuskiewicz,Philippe Prokocimer +6 more
TL;DR: Tedizolid, given orally or intravenously at 200 mg, has a favorable safety profile, and tolerability in clinically important subpopulations appeared comparable to the overall population.
Journal ArticleDOI
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial
Jonathan A. Robbins,Dereck Tait,Qinlei Huang,Sheri Dubey,Tami Crumley,Josee Cote,Julie Ann Luk,Jeffrey R. Sachs,Kathryn Tucker Rutkowski,Harriet Park,Robert Schwab,William Joseph Howitt,Juan Rondon,Martha Hernandez-Illas,Terry E. O'Reilly,William B. Smith,Jakub K. Simon,Cathy Hardalo,Xuemei Zhao,Richard Wnek,Alethea Cope,Eseng Lai,Paula W. Annunziato,Dalya Guris,S. Aubrey Stoch +24 more
TL;DR: In this article , the safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19 vaccine candidate, were reported.
Journal ArticleDOI
Myelosuppression with Oxazolidinones: Are There Differences?
TL;DR: Comparing thrombocytopenia events in association with tedizolid and linezolid from the FDA Adverse Event Reporting System (FAERS), a database of voluntary spontaneous AE reports submitted to the FDA, is read with interest.